Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CROs Highlight Toxicology Revenue; Are Mergers Non-Toxic To Bottom Line?

Executive Summary

Covance expects its expanding toxicology research to drive double-digit revenue growth through 2003

You may also be interested in...

Pfizer $11 Bil. Premium For Pharmacia Calibrated To Merger Savings

Pfizer's $11 bil. premium above Pharmacia's recent stock market valuation is a figure calculated from the estimated operating savings in the companies' proposed stock-for-stock transaction

Corcept To Test Sluggish IPO Market For Biotechs

Corcept Therapeutics will test the sluggish market for biopharmaceutical initial public offerings with an IPO slated for June 10

Covance Manufacturing Divestment To Fund $20 Mil. Toxicology Expansion

Covance will use cash generated from the divestment of its biomanufacturing business to fund capacity expansion for its Madison, Wisc., toxicology facility, CEO Chris Kuebler told analysts.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts